Lin Xichen 4

What Happened

• Lin Xichen, Chief Scientific Officer of Structure Therapeutics (GPCR), received equity awards on March 19, 2026: 43,368 ordinary shares and 53,703 derivative awards (RSUs), for a total of 97,071 shares granted at $0.00 per share. These were reported on a Form 4 filed March 23, 2026. The awards were grants (code A) — not open‑market purchases or sales.

Key Details

• Transaction date: 2026-03-19; Form 4 filed: 2026-03-23 (filed timely).
• Grant amounts and price: 43,368 shares @ $0.00 (acquired) and 53,703 derivative shares @ $0.00 (acquired); combined = 97,071 shares.
• ADS conversion: 1 ADS = 3 ordinary shares (footnote); 97,071 ordinary shares ≈ 32,357 ADSs.
• Vesting/terms: Footnote F2 states the RSUs vest 1/4 annually on each anniversary of March 1, 2026, subject to continued service. Footnotes F3 and F4 describe standard option pricing/vesting language but no option exercise was reported in this filing.
• Shares owned after the transaction were not specified in the provided excerpt of the filing.
• No 10b5‑1 plan, tax‑withholding sale, or late‑filing indication was disclosed in the provided notes.

Context

• These grants are awards (compensation), not purchases — they reflect compensation/retention incentives rather than an immediate market buy or sell signal. The RSUs are contingent and vest over time, so economic ownership and transferability may be limited until vesting conditions are met.